Depressive disorders account for a substantial global burden of disease, often resistant to conventional pharmacotherapies that primarily target monoaminergic systems. This clinical challenge has propelled researchers to reconsider compounds long marginalized by restrictive drug policies. Psychedelics such as psilocybin and LSD, alongside dissociative anesthetics like ketamine and its enantiomer esketamine, have garnered attention because of their rapid and sustained antidepressant effects after only one or a few administrations. The study elucidates how these agents diverge from traditional antidepressants by engaging distinct neurobiological pathways that promote neuroplasticity and circuit reconfiguration.

At the cellular level, psychedelics exert their effects predominantly through agonism of the serotonin 2A receptor (5-HT2AR), which is richly expressed in the cortex. Activation of this receptor initiates a cascade of intracellular events leading to the upregulation of brain-derived neurotrophic factor (BDNF) and the mammalian target of rapamycin (mTOR) signaling pathways. These molecular responses foster synaptogenesis—a crucial process for rewiring maladaptive neural networks implicated in depression. Importantly, the temporal dynamics of these changes challenge the traditional view of antidepressant action, with synaptic remodeling occurring much more rapidly than seen with selective serotonin reuptake inhibitors (SSRIs).

Ketamine and esketamine, meanwhile, operate through a different mechanism involving noncompetitive antagonism of the N-methyl-D-aspartate receptor (NMDAR). This blockade leads to a paradoxical increase in glutamate release and subsequent stimulation of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors (AMPARs), culminating in downstream mTOR activation and enhanced synaptic connectivity. The research further highlights esketamine’s unique pharmacokinetic profile, conferring a more favorable side effect spectrum and making it more amenable to clinical use in treatment-resistant depression.

Neuroimaging modalities including functional MRI (fMRI) and positron emission tomography (PET) have been instrumental in mapping the real-time impact of psychedelics and ketamine on brain function. The article reveals that these agents normalize aberrant activity within the default mode network (DMN), a collection of interconnected brain regions that become hyperactive during depressive rumination. Reductions in DMN activity correspond with clinical improvements, underscoring an essential mechanism by which these treatments alleviate symptoms. Moreover, enhanced connectivity between prefrontal and limbic regions reflects a restoration of top-down regulatory control over emotional processing circuits.

The authors place particular emphasis on the neuroplastic effects as a central theme that integrates molecular, network-level, and behavioral changes. Enhanced plasticity allows the brain to escape entrenched pathological states and adopt healthier patterns of information processing. This conceptual advancement shifts the therapeutic focus from merely correcting neurotransmitter imbalances to actively promoting brain remodeling. Unique to psychedelics is their ability to produce a subjective “mystical experience,” which correlates with long-term remission, suggesting that psychological effects and biological mechanisms are deeply intertwined in the healing process.

Clinically, the study provides a thorough overview of randomized controlled trials and open-label studies indicating rapid onset of antidepressant effects, often within hours or days after administration—dramatically faster than standard antidepressants. The durability of responses is particularly noteworthy, with some patients maintaining remission for weeks or months following a limited number of doses. This challenges current treatment paradigms and suggests a potential shift towards episodic rather than continuous pharmacotherapy.

Safety and tolerability are also reviewed extensively. While psychedelics carry a historical stigma due to their psychoactive properties, contemporary clinical protocols emphasize controlled settings with professional supervision, thereby minimizing risks. Ketamine and esketamine’s side effect profiles, such as dissociation and transient increases in blood pressure, are documented alongside mitigation strategies. The authors advocate for rigorous screening and monitoring to ensure patient safety.

The integration of neuroimaging biomarkers with clinical outcomes offers a promising avenue for personalizing treatment. By identifying individuals who exhibit neurobiological signatures predictive of positive response, clinicians could tailor interventions more effectively. The review underscores the need for further research into candidate biomarkers such as 5-HT2AR density, mTOR pathway activation markers, and functional connectivity patterns to optimize therapeutic efficacy.

Importantly, the article addresses the ethical and regulatory dimensions of incorporating psychedelics and ketamine/esketamine into mainstream psychiatric practice. It calls for an evidence-based framework that balances rapid clinical innovation with appropriate patient protections, urging policymakers to consider their reclassification for medical use. The authors advocate for multidisciplinary collaboration among neuroscientists, clinicians, and ethicists to navigate the complexities of implementation.

The translational implications of this research are profound. By elucidating the convergent molecular pathways and neurocircuitry changes underpinning the antidepressant effects of these compounds, the study paves the way for the development of next-generation therapeutics. These could include novel agents that retain the rapid plasticity-enhancing benefits without the psychoactive properties or adverse effects, representing a new frontier in psychopharmacology.

In conclusion, this comprehensive synthesis reframes psychedelics and ketamine/esketamine not simply as alternatives to conventional antidepressants but as powerful agents capable of fundamentally altering the neural substrates of depression. Their ability to induce rapid and durable remission, combined with mechanistic insights derived from advanced neuroimaging and molecular biology, marks a paradigm shift in the understanding and treatment of depressive disorders. As research progresses, these findings hold promise for transforming clinical practice and offering renewed hope to millions affected by this pervasive condition.

Subject of Research: Psychedelics and ketamine/esketamine use in depressive disorders focusing on biological mechanisms, neuroimaging findings, and clinical outcomes.

Article Title: Psychedelics and ketamine/esketamine in depressive disorders: biological mechanisms and associated neuroimaging and clinical changes.

Article References:
d’Andrea, G., Chiappini, S., Ciavoni, L. et al. Psychedelics and ketamine/esketamine in depressive disorders: biological mechanisms and associated neuroimaging and clinical changes. Transl Psychiatry 15, 453 (2025). https://doi.org/10.1038/s41398-025-03654-3

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41398-025-03654-3

Chronic stress exerts a pervasive and deleterious impact on brain structure and function, principally via sustained activation of the hypothalamic-pituitary-adrenal (HPA) axis. This persistent neuroendocrine dysregulation precipitates neuronal remodeling and synaptic deficits in key regions governing mood and cognition. Traditional pharmacological interventions, predominantly selective serotonin reuptake inhibitors (SSRIs), and psychotherapeutic modalities such as cognitive behavioral therapy, although beneficial for subsets of patients, frequently leave a substantial proportion with refractory symptoms or intolerable side effects. Against this backdrop, psychedelics have reemerged as a promising avenue, rekindling scientific inquiry long dormant since regulatory barriers imposed in the late 20th century.

Central to their mechanism of action is the potent agonism of serotonin 2A (5-HT2A) receptors, which are densely expressed in cortical areas implicated in emotional regulation and higher-order cognitive functions. Activation of these receptors initiates complex intracellular cascades that culminate in enhanced neuroplasticity. Notably, preclinical models reveal that psilocybin elevates brain-derived neurotrophic factor (BDNF) levels and promotes dendritic arborization within the prefrontal cortex. These neuroplastic adaptations are critical, as they restore synaptic connectivity disrupted by chronic glucocorticoid exposure, offering a biological substrate for sustained mood improvement.

Clinically, an accumulating corpus of evidence underscores the durable efficacy of psychedelic-assisted therapies. Psilocybin, administered in controlled settings, has demonstrated remarkable antidepressant effects in individuals unresponsive to conventional treatments, with symptom remission extending several months post-intervention. Of particular note, MDMA-assisted psychotherapy has yielded profound reductions in PTSD symptomatology, with approximately two-thirds of participants no longer meeting diagnostic criteria following treatment. Nonetheless, regulatory authorities including the FDA have cautioned regarding methodological limitations inherent in current trials, emphasizing the necessity for rigorous, large-scale investigations with refined protocols.

The authors advance an insightful conceptualization that psychedelics do more than transiently ameliorate symptoms; they catalyze neurobiological processes that may underpin fundamental recovery. By fostering a neuroplastic milieu, these compounds facilitate the reprocessing and integration of entrenched traumatic memories and stressors, potentially obviating relapse common with standard treatments. This paradigm shift from symptomatic palliation to mechanistic restoration heralds a new frontier in psychiatric care.

Beyond serotonergic modulation, burgeoning evidence implicates psychedelics in attenuating neuroinflammation, a pathophysiological axis increasingly recognized in stress-related disorders. Psilocybin appears to downregulate pro-inflammatory cytokines, which may otherwise perpetuate neural damage. The authors advocate for concurrent biomarker assessments—encompassing both immune parameters and cortisol dynamics—to elucidate the interplay between these mechanisms and optimize therapeutic strategies.

Distinct from classical psychedelics, MDMA’s therapeutic efficacy is attributed to its entactogenic profile mediated through monoamine release, engendering heightened emotional openness and attenuated fear responses. This pharmacodynamic state enhances memory reconsolidation during psychotherapy, enabling patients to confront traumatic content without overwhelming distress, thus reinforcing lasting psychological gains.

Despite these promising advances, the article does not shy away from the formidable challenges impeding mainstream adoption. The entrenched Schedule I classification poses significant barriers to research and clinical implementation, though evolving legislative experiments in jurisdictions like Oregon and Colorado signal gradual shifts towards regulated frameworks. The necessity of specialized clinician training, given the unique therapeutic milieu and psychological effects, is underscored as essential for safe and effective administration.

Safety considerations remain paramount. Common acute adverse effects such as nausea, headache, and transient cardiovascular changes require meticulous screening and intra-session monitoring. The authors recommend standardization of clinical protocols, enhanced adverse event reporting, and innovative methodological approaches to mitigate expectancy biases that can confound efficacy assessments. Moreover, longitudinal comparative studies contrasting psychedelic-assisted therapy with established interventions across diverse psychiatric populations are crucial to delineate long-term outcomes.

Looking ahead, Prof. Wang and colleagues delineate critical frontiers for future research. Precision medicine approaches, including development of predictive biomarkers and identification of genetic moderators, could personalize dosing and optimize patient selection. Additionally, interdisciplinary collaboration spanning neuroscience, psychology, bioengineering, and pharmacology is vital to unravel the complex neural circuitry and molecular pathways modulated by psychedelics.

This synthesized viewpoint serves as a pivotal resource, weaving together historical context, mechanistic insights, clinical realities, and policy considerations into a coherent framework. It equips researchers, clinicians, and policymakers with a nuanced understanding requisite for responsibly harnessing psychedelics’ therapeutic promise. The authors’ integrative analysis highlights patterns and contradictions across the literature, illuminating the most auspicious avenues for advancing this rapidly evolving domain.

In summary, the resurgence of psychedelic research marks a renaissance in psychiatric therapeutics. By engaging serotonin 2A receptor-mediated neuroplasticity, mitigating neuroinflammation, and facilitating profound psychotherapeutic processes, these compounds offer a novel means to counterbalance the pernicious effects of chronic stress. While substantive challenges remain, including regulatory constraints, safety management, and the need for rigorous clinical validation, the horizon for mental health treatment is undeniably expanding, catalyzed by these powerful agents.

The full peer-reviewed viewpoint, entitled “Psychedelics in the context of stress and psychiatric disorders: A new horizon in mental health treatment,” is openly accessible in Psychedelics as of 29 September 2025. This article epitomizes the dynamic intersection of cutting-edge science and clinical innovation, promising to reshape the landscape of mental health care in the decades to come.

Subject of Research: People

Article Title: Psychedelics in the context of stress and psychiatric disorders: A new horizon in mental health treatment

News Publication Date: 14-Oct-2025

Web References:
http://dx.doi.org/10.61373/pp025v.0038

Image Credits: XiaohuiWang

Keywords

Psychedelics, 5-HT2A receptor, neuroplasticity, brain-derived neurotrophic factor, psilocybin, MDMA, stress, psychiatric disorders, PTSD, depression, neuroinflammation, therapeutic mechanisms